Powered by Google Google ÜbersetzerGoogle Übersetzer
Originaltext
Diese Übersetzung bewerten
Mit deinem Feedback können wir Google Übersetzer weiter verbessern
Latest Press Releases
View all
TimeHeadline
Just nowPress Release Apr 29 2026
11m agoWebull to Release First Quarter 2026 Results on May 21, 2026
11m agoArdmore Shipping Provides Update on Fleet Investment, Dividend Policy, and Vessel Sale
11m agoSilvercrest Establishes Atlanta Office, Hires Brittain Prigge
12m agoBiomerica’s inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026

Vivosim Labs, Inc.

About

Vivosim Labs, Inc. (NASDAQ:VIVS) — investor relations, events, news, and company updates on 6ix.

Latest News

Yesterday
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
Apr 1 2026
VivoSim Announces Pricing of up to a $4 Million Public Offering
Mar 24 2026
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
Mar 3 2026
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
Feb 11 2026
VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego

Financials

Revenue
$142 K
Market Cap
$4.43 M
P/E Ratio
0.87
EPS
1.76

Community Chat

Ask AI

6ix6ix